The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Xeris Biopharma Holdings's share price is $1.76.
Xeris Biopharma Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.19. Hence, Xeris Biopharma Holdings's PS Ratio for today is 1.48.
Good Sign:
Xeris Biopharma Holdings Inc stock PS Ratio (=1.48) is close to 1-year low of 1.42
The historical rank and industry rank for Xeris Biopharma Holdings's PS Ratio or its related term are showing as below:
XERS'
s PS Ratio Range Over the Past 10 Years
Min: 1.29 Med: 7.11 Max: 142.79
Current: 1.48
During the past 8 years, Xeris Biopharma Holdings's highest PS Ratio was 142.79. The lowest was 1.29. And the median was 7.11.
XERS's PS Ratio is ranked better than 88.4% of 1000
companies
in the Biotechnology industry
Industry Median: 9.095
vs XERS: 1.48
During the past 8 years, Xeris Biopharma Holdings's highest 3-Year average Revenue per Share Growth Rate was 98.50% per year. The lowest was -40.60% per year. And the median was 35.50% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Xeris Biopharma Holdings's PS Ratio
For the Biotechnology subindustry, Xeris Biopharma Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's PS Ratio falls into.
Xeris Biopharma Holdings PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Xeris Biopharma Holdings's Share Price of today is $1.76. Xeris Biopharma Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.19.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Xeris Biopharma Holdings (NAS:XERS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Xeris Biopharma Holdings PS Ratio Related Terms
Thank you for viewing the detailed overview of Xeris Biopharma Holdings's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Xeris Biopharma Holdings (Xeris Biopharma Holdings) Business Description
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XERS has been successfully added to your 